Advances in systemic therapies have significantly enhanced survival outcomes for patients with metastatic breast cancer. As of 2020, treatment paradigms emphasize tailoring therapy to tumor biology, incorporating factors such as hormone receptor status, HER2 expression, and molecular subtype. Adherence to NCCN guidelines facilitates evidence-based decision-making, optimizing patient outcomes. Emerging therapeutic strategies continue to evolve the management of metastatic breast cancer, underscoring the importance of nuanced, biology-driven treatment selection.